Roman Kasianov

Alpenglow Biosciences, a spatial biology company focused on 3D imaging, presented a new imaging interface, titled "LUMI", for light-sheet microscopy at the Association of Biomolecular Resource Facilities (ABRF) 2025 Annual Meeting, held from March 23 to 26 in Las Vegas.

ReactWise, a UK-based startup developing AI-driven robotic laboratories for pharmaceutical and chemical manufacturing, has raised $3.4 million in pre-seed funding. The round includes $500,000 from Y Combinator, a £1.2 million (around $1.6 million) grant from Innovate UK, and $1.5 million from unnamed venture capitalists and angel investors. 

According to ReactWise, the funding will support the expansion of its AI models and automation platform, which is designed to accelerate process development by up to 30 times.

VantAI, a NY-based spinout of Roivant founded in 2019, has introduced Neo-1, an artificial intelligence model that integrates atomic-level biomolecule structure prediction with molecular generation in a single framework.

Ampersand Biomedicines has raised $65 million in a Series B funding round, with participation from Eli Lilly and Company and founding firm Flagship Pioneering. The funding will be used to complete preclinical development of two immunological drug candidates—one for inflammation and the other for cancer. This is Ampersand’s first external financing since its launch with $50 million from Flagship Pioneering two years ago.

Proscia, a developer of AI-based pathology software, has raised $50 million in funding, bringing its total capital raised to $130 million. 

The funding round was led by Insight Partners, with participation from AI Capital Partners, Triangle Peak Partners, Avenue Venture Opportunities Fund, Emerald Development Managers, GPG Healthcare, Fusion Fund, Interwoven Ventures, and Razor’s Edge. The company plans to use the funds to grow its customer base and expand the core AI capabilities of its Concentriq platform.

Synchron, a developer of implantable brain-computer interface (BCI) technology, has announced a collaboration with NVIDIA to enhance its next-generation BCI using the NVIDIA Holoscan platform. The partnership, announced at the 2025 JP Morgan Healthcare Conference, aims to improve real-time neural processing and explore large-scale brain-language modeling.

Elsevier launched ScienceDirect AI, a new generative AI tool designed to help researchers quickly access and summarize key findings from millions of peer-reviewed research articles and book chapters. The tool, launched on March 12, 2025, is integrated with ScienceDirect, Elsevier’s platform that houses 22 million scientific publications.

Tempus AI has announced the acquisition of a clinical trial matching platform Deep 6 AI, which applies artificial intelligence (AI) to streamline patient recruitment and real-world evidence generation. The acquisition adds over 750 provider sites and more than 30 million patients to Tempus' clinical trial network, according to the company’s statement.

Insilico Medicine has raised $110 million in Series E funding to support clinical trials and further develop its AI-driven drug discovery programs. The round was led by Hong Kong‑based Value Partners, with participation from existing backers including Warburg Pincus, OrbiMed Advisors, and Eli Lilly’s venture arm, as well as new, undisclosed investors. This funding has brought the company’s valuation to over $1 billion, according to Bloomberg.

Flagship Pioneering has announced the launch of Lila Sciences, a company developing an AI-based platform designed to automate scientific experimentation and discovery. 

Lila’s platform combines generative AI with autonomous lab systems to create a closed-loop process where AI generates hypotheses, designs experiments, executes them using robotics, and refines future models based on experimental results. This feedback cycle is intended to accelerate research by allowing AI to adjust and improve its predictions through direct experimental outcomes.